Kamat - Figure 18

European Organization for Research and Treatment of Cancer (EORTC) 30962 study

References

[19]

Oddens J, Brausi M, Sylvester R, et al. Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guérin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance. Eur Urol. 2013;63:462−72  http://dx.doi.org/10.1016/j.eururo.2012.10.039